We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » DOJ Probes Sanofi, GSK for Failure to Disclose Contaminated Zantac
DOJ Probes Sanofi, GSK for Failure to Disclose Contaminated Zantac
Sanofi and GlaxoSmithKline announced in Security Exchange Commission (SEC) filings that the Department of Justice and the U.S. Attorney’s Office for the Eastern District of Pennsylvania have opened an investigation into their reporting of potentially contaminated Zantac (ranitidine).